125 related articles for article (PubMed ID: 3171246)
1. The long-term stability of recombinant (serine-17) human interferon-beta.
Geigert J; Panschar BM; Fong S; Huston HN; Wong DE; Wong DY; Taforo C; Pemberton M
J Interferon Res; 1988 Aug; 8(4):539-47. PubMed ID: 3171246
[TBL] [Abstract][Full Text] [Related]
2. Potency stability of recombinant (Serine-17) human interferon-beta.
Geigert J; Ziegler DL; Panschar BM; Creasey AA; Vitt CR
J Interferon Res; 1987 Apr; 7(2):203-11. PubMed ID: 3039014
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).
Runkel L; Meier W; Pepinsky RB; Karpusas M; Whitty A; Kimball K; Brickelmaier M; Muldowney C; Jones W; Goelz SE
Pharm Res; 1998 Apr; 15(4):641-9. PubMed ID: 9587963
[TBL] [Abstract][Full Text] [Related]
4. Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains.
Ruzicka FJ; Jach ME; Borden EC
J Biol Chem; 1987 Nov; 262(33):16142-9. PubMed ID: 2960673
[TBL] [Abstract][Full Text] [Related]
5. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
[TBL] [Abstract][Full Text] [Related]
7. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
Ruzicka FJ; Schmid SM; Groveman DS; Cummings KB; Borden EC
Cancer Res; 1987 Sep; 47(17):4582-9. PubMed ID: 2957045
[TBL] [Abstract][Full Text] [Related]
8. [Obtaining human recombinant (serine-17) beta-interferon by the method of oligonucleotide-directed mutagenesis and its expression in Escherichia coli].
Shekhter II; Beĭko VP; Bulenkov MT; Khodova OM; Kolevatykh MA; Izotova LS; Lebedeva MI; Rudenskiĭ AIu; Borukhov SI; Iurin VI
Antibiot Khimioter; 1991 Aug; 36(8):25-8. PubMed ID: 1755705
[TBL] [Abstract][Full Text] [Related]
9. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD; Metch B; Lucas JG; Balcerzak SP; Grunberg SM; Rivkin SE
J Interferon Res; 1990 Oct; 10(5):531-4. PubMed ID: 2273299
[TBL] [Abstract][Full Text] [Related]
11. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers.
Higgins PG; Al-Nakib W; Willman J; Tyrrell DA
J Interferon Res; 1986 Apr; 6(2):153-9. PubMed ID: 3014018
[TBL] [Abstract][Full Text] [Related]
12. An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice.
Abdolvahab MH; Fazeli A; Radmalekshahi M; Nejadnik MR; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Mar; 36(3):192-203. PubMed ID: 26824268
[TBL] [Abstract][Full Text] [Related]
13. Characterization of E. coli-derived recombinant human interferon-beta as compared with fibroblast human interferon-beta.
Utsumi J; Yamazaki S; Hosoi K; Kimura S; Hanada K; Shimazu T; Shimizu H
J Biochem; 1987 May; 101(5):1199-208. PubMed ID: 3308862
[TBL] [Abstract][Full Text] [Related]
14. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
Schiller JH; Horisberger MA; Bittner G; Carlin JM; Storer B; Byrne GI; Willson JK; Borden EC
J Biol Response Mod; 1990 Aug; 9(4):368-77. PubMed ID: 2395002
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant interferon-beta ser on primary human tumor colony-forming units.
Von Hoff DD; Huong AM
J Interferon Res; 1988 Dec; 8(6):813-20. PubMed ID: 3230332
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Rosenblum MG; Yung WK; Kelleher PJ; Ruzicka F; Steck PA; Borden EC
J Interferon Res; 1990 Apr; 10(2):141-51. PubMed ID: 2140395
[TBL] [Abstract][Full Text] [Related]
17. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
18. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
20. Betaseron.
Lin L
Dev Biol Stand; 1998; 96():97-104. PubMed ID: 9890522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
